GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

Kirkland, Latham, Paul Weiss and others have replaced the likes of Sullivan & Cromwell, Clifford Chance and Slaughter and May ...

GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer ...

DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Marketing: Around the world, brands have learnt that revamping their identities without thinking the exercise through can be met with ridicule and derision — often the hard way. On the other hand, ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.